2025 Q4 -tulosraportti
20 päivää sitten
‧42 min
61,20 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 | - | - | ||
| 9 | - | - | ||
| 2 | - | - | ||
| 15 | - | - | ||
| 20 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 779 | 15 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 779 | 15 779 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
10.3.10.3.AbbVie kom ind på ABBV-295 til Leerink Global Health i dag: We're quite encouraged by the data, David. We are seeing almost a 10% efficacy delta only at 12 weeks. And what's really encouraging is that the population studied was not an obese population on average. Meaning the BMI that we studied was more in a healthy population under 30, and majority male, only 12% of that population was female. And majority percentage of weight loss usually occurs in higher BMI settings and when there's more women in the trial and usually beyond 12 weeks. So we had the disadvantage of not having any of those 3 factors in the study and still saw an almost 10% delta in the higher treatment arms. And one of them was actually every other week. So that sets up a potential of a profile that could be every other week, potentially even monthly favorable safety profile and room to move on efficacy as we move into the relevant patient population and treat longer. So we're very enthusiastic about moving into Phase Ib, which will include patients that have, I would say, real obesity. We also have the opportunity to study a dose higher than the 14-milligram studied. And in fact, the 14 milligrams was only given for 1 week before the weight was observed in this study. So longer duration, potentially higher dose and the right patient population for us, I think it was not anticipated to be this good. So we're very excited to move this forward. And then kicking off a Phase II also later this year to further optimize the dose. We want the best tolerability we can get to drive durability. And then to optimize the weight loss, which is already fairly substantial only in week 12. David Risinger Leerink Partners LLC, Research Division Excellent. And what was the average BMI of patients that were... Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer I think it was 29 and change. Just under 30. David Risinger Leerink Partners LLC, Research Division Got it. Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer Typically, you would see 35, 36 above that. David Risinger Leerink Partners LLC, Research Division Yes, very impressive. And how have you discussed the balance between amylin and calcitonin for this agent? Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer Well, you're right. It is a DACRA format, so it binds both. And we don't see any detriment to weight loss, where I think there were some arguments that you could be better off, specifically going after amylin. We haven't observed that. There could be a benefit potentially to bone if you also target calcitonin. So we will learn more about this over time when we're able to do DEXA scans, also MRIs to understand the full metabolic impact whether that's bone. And then the distribution between fat and muscle. So we'll be collecting all of that over time. But so far, encouraged by the DACRA mechanism of this based on the weight loss that we've seen thus far in the wrong patient population in a way.
·11.3.But why not optimize it, now that the opportunity is there? It can't be that hard to put together an optimal group, can it?- ·9.3.AbbVie naturally has significantly more analyst attention than Gubra, so a couple of comments on the data have, of course, come in: BMO Capital: “Differences in the baseline BMI and male enrollment in each of the study populations make comparisons to other assets like Lilly’s eloralintide more challenging,” BMO said, “but efficacy even at extended dosing intervals for ABBV-295 is encouraging.” William Blair: “[W]e believe the week 12 weight loss of roughly 10% is competitive across the amylin class, and therefore is an encouraging initial update” RBC Capital Markets: new data “demonstrate, in our view, a solid profile in the amylin class where there is growing excitement for ABBV given their market-leading position in the aesthetics space and the accelerating trend towards a DTC model for obesity medications.” https://www.biospace.com/drug-development/abbvies-amylin-candidate-competitive-in-early-stage-trial
·9.3.ABBV-295 (from Gubra)shows weight reduction of just under 10 pct. after 12 weeks. Petrelintide (from Zealand) shows weight reduction of well over 10 pct. after 42 weeks. And in the case of ABBV-295, the trial was conducted on a group primarily of men with only moderate overweight! Whats not to like? (I have indeed bought in and added at 300).
·9.3.Unfortunately, I didn't have anything to buy with, but I think it can end in plus by the end of the day 
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
20 päivää sitten
‧42 min
61,20 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 10.3.10.3.AbbVie kom ind på ABBV-295 til Leerink Global Health i dag: We're quite encouraged by the data, David. We are seeing almost a 10% efficacy delta only at 12 weeks. And what's really encouraging is that the population studied was not an obese population on average. Meaning the BMI that we studied was more in a healthy population under 30, and majority male, only 12% of that population was female. And majority percentage of weight loss usually occurs in higher BMI settings and when there's more women in the trial and usually beyond 12 weeks. So we had the disadvantage of not having any of those 3 factors in the study and still saw an almost 10% delta in the higher treatment arms. And one of them was actually every other week. So that sets up a potential of a profile that could be every other week, potentially even monthly favorable safety profile and room to move on efficacy as we move into the relevant patient population and treat longer. So we're very enthusiastic about moving into Phase Ib, which will include patients that have, I would say, real obesity. We also have the opportunity to study a dose higher than the 14-milligram studied. And in fact, the 14 milligrams was only given for 1 week before the weight was observed in this study. So longer duration, potentially higher dose and the right patient population for us, I think it was not anticipated to be this good. So we're very excited to move this forward. And then kicking off a Phase II also later this year to further optimize the dose. We want the best tolerability we can get to drive durability. And then to optimize the weight loss, which is already fairly substantial only in week 12. David Risinger Leerink Partners LLC, Research Division Excellent. And what was the average BMI of patients that were... Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer I think it was 29 and change. Just under 30. David Risinger Leerink Partners LLC, Research Division Got it. Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer Typically, you would see 35, 36 above that. David Risinger Leerink Partners LLC, Research Division Yes, very impressive. And how have you discussed the balance between amylin and calcitonin for this agent? Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer Well, you're right. It is a DACRA format, so it binds both. And we don't see any detriment to weight loss, where I think there were some arguments that you could be better off, specifically going after amylin. We haven't observed that. There could be a benefit potentially to bone if you also target calcitonin. So we will learn more about this over time when we're able to do DEXA scans, also MRIs to understand the full metabolic impact whether that's bone. And then the distribution between fat and muscle. So we'll be collecting all of that over time. But so far, encouraged by the DACRA mechanism of this based on the weight loss that we've seen thus far in the wrong patient population in a way.·11.3.But why not optimize it, now that the opportunity is there? It can't be that hard to put together an optimal group, can it?
- ·9.3.AbbVie naturally has significantly more analyst attention than Gubra, so a couple of comments on the data have, of course, come in: BMO Capital: “Differences in the baseline BMI and male enrollment in each of the study populations make comparisons to other assets like Lilly’s eloralintide more challenging,” BMO said, “but efficacy even at extended dosing intervals for ABBV-295 is encouraging.” William Blair: “[W]e believe the week 12 weight loss of roughly 10% is competitive across the amylin class, and therefore is an encouraging initial update” RBC Capital Markets: new data “demonstrate, in our view, a solid profile in the amylin class where there is growing excitement for ABBV given their market-leading position in the aesthetics space and the accelerating trend towards a DTC model for obesity medications.” https://www.biospace.com/drug-development/abbvies-amylin-candidate-competitive-in-early-stage-trial
- ·9.3.ABBV-295 (from Gubra)shows weight reduction of just under 10 pct. after 12 weeks. Petrelintide (from Zealand) shows weight reduction of well over 10 pct. after 42 weeks. And in the case of ABBV-295, the trial was conducted on a group primarily of men with only moderate overweight! Whats not to like? (I have indeed bought in and added at 300).·9.3.Unfortunately, I didn't have anything to buy with, but I think it can end in plus by the end of the day 
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 | - | - | ||
| 9 | - | - | ||
| 2 | - | - | ||
| 15 | - | - | ||
| 20 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 779 | 15 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 779 | 15 779 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
2025 Q4 -tulosraportti
20 päivää sitten
‧42 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 27.2. | ||
2025 Q3 -tulosraportti 7.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 9.5.2025 | ||
2024 Q4 -tulosraportti 28.2.2025 |
61,20 DKK/osake
Viimeisin osinko
0,00%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- 10.3.10.3.AbbVie kom ind på ABBV-295 til Leerink Global Health i dag: We're quite encouraged by the data, David. We are seeing almost a 10% efficacy delta only at 12 weeks. And what's really encouraging is that the population studied was not an obese population on average. Meaning the BMI that we studied was more in a healthy population under 30, and majority male, only 12% of that population was female. And majority percentage of weight loss usually occurs in higher BMI settings and when there's more women in the trial and usually beyond 12 weeks. So we had the disadvantage of not having any of those 3 factors in the study and still saw an almost 10% delta in the higher treatment arms. And one of them was actually every other week. So that sets up a potential of a profile that could be every other week, potentially even monthly favorable safety profile and room to move on efficacy as we move into the relevant patient population and treat longer. So we're very enthusiastic about moving into Phase Ib, which will include patients that have, I would say, real obesity. We also have the opportunity to study a dose higher than the 14-milligram studied. And in fact, the 14 milligrams was only given for 1 week before the weight was observed in this study. So longer duration, potentially higher dose and the right patient population for us, I think it was not anticipated to be this good. So we're very excited to move this forward. And then kicking off a Phase II also later this year to further optimize the dose. We want the best tolerability we can get to drive durability. And then to optimize the weight loss, which is already fairly substantial only in week 12. David Risinger Leerink Partners LLC, Research Division Excellent. And what was the average BMI of patients that were... Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer I think it was 29 and change. Just under 30. David Risinger Leerink Partners LLC, Research Division Got it. Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer Typically, you would see 35, 36 above that. David Risinger Leerink Partners LLC, Research Division Yes, very impressive. And how have you discussed the balance between amylin and calcitonin for this agent? Roopal Thakkar Executive VP of Research & Development and Chief Scientific Officer Well, you're right. It is a DACRA format, so it binds both. And we don't see any detriment to weight loss, where I think there were some arguments that you could be better off, specifically going after amylin. We haven't observed that. There could be a benefit potentially to bone if you also target calcitonin. So we will learn more about this over time when we're able to do DEXA scans, also MRIs to understand the full metabolic impact whether that's bone. And then the distribution between fat and muscle. So we'll be collecting all of that over time. But so far, encouraged by the DACRA mechanism of this based on the weight loss that we've seen thus far in the wrong patient population in a way.·11.3.But why not optimize it, now that the opportunity is there? It can't be that hard to put together an optimal group, can it?
- ·9.3.AbbVie naturally has significantly more analyst attention than Gubra, so a couple of comments on the data have, of course, come in: BMO Capital: “Differences in the baseline BMI and male enrollment in each of the study populations make comparisons to other assets like Lilly’s eloralintide more challenging,” BMO said, “but efficacy even at extended dosing intervals for ABBV-295 is encouraging.” William Blair: “[W]e believe the week 12 weight loss of roughly 10% is competitive across the amylin class, and therefore is an encouraging initial update” RBC Capital Markets: new data “demonstrate, in our view, a solid profile in the amylin class where there is growing excitement for ABBV given their market-leading position in the aesthetics space and the accelerating trend towards a DTC model for obesity medications.” https://www.biospace.com/drug-development/abbvies-amylin-candidate-competitive-in-early-stage-trial
- ·9.3.ABBV-295 (from Gubra)shows weight reduction of just under 10 pct. after 12 weeks. Petrelintide (from Zealand) shows weight reduction of well over 10 pct. after 42 weeks. And in the case of ABBV-295, the trial was conducted on a group primarily of men with only moderate overweight! Whats not to like? (I have indeed bought in and added at 300).·9.3.Unfortunately, I didn't have anything to buy with, but I think it can end in plus by the end of the day 
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 10 | - | - | ||
| 9 | - | - | ||
| 2 | - | - | ||
| 15 | - | - | ||
| 20 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 779 | 15 779 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 15 779 | 15 779 | 0 | 0 |